Companies testify to clinical gains from AI: stroke triage, earlier detection and fewer readmissions

Two vendors described clinical results their companies reported from deployment of AI tools in frontline care.

Dr. Andrew Ibrahim, chief clinical officer at Viz.ai, said his company's AI platform automatically analyzes CT scans to identify conditions like large vessel occlusion strokes, alerts stroke teams in real time and assembles clinical information for urgent decisions. ‘‘Independent studies show that this reduces treatment time by more than 30 minutes, [and] insurance hospital stays by as much as 3 days,’’ he told the subcommittee, and said Viz.ai’s platform supports care at more than 1,800 hospitals nationwide.

Andrew Toye, CEO of Clover Health, described metrics from the company’s Medicare Advantage deployments, saying clinicians using Clover Assistant identify diabetes about three years earlier on average, detect kidney disease 1.5 years earlier, and achieve higher preventive screening rates (about 11 percent more colorectal cancer screening and nearly 5 percent more breast cancer screening). Toye said certain cohorts experienced 18 percent fewer hospital stays and 25 percent fewer readmissions, and that those clinical improvements translated to better cost ratios for the plan.

Both witnesses and members stressed safeguards: they described human‑in‑the‑loop workflows, institution‑level validation before deployment and continuous monitoring after deployment. Witnesses said interoperability, access to data and appropriate reimbursement models are necessary for smaller or rural providers to realize similar gains.